We assessed the efficacy of olaparib, cisplatin and their combination in the Brca1-deficient models after two weeks of treatment (Fig. 3D, E) by measuring relative tumor volumes (RTV), the tumor volume changes from baseline (pre-dosing) to the end-point as determined by MRI. The gene discussed is BRCA1; the disease is neoplasm.